Cocrystal Pharma (COCP) vs NewcelX (NCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Cocrystal Pharma (COCP) has outperformed NewcelX (NCEL) over the past year, losing 12.3% versus a loss of 83.7%. Over five years, COCP leads with a -90.5% price change compared with -99.7% for NCEL. Cocrystal Pharma is the larger company by market cap ($20.6 million vs $17.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COCP | NCEL |
|---|---|---|
| Share price | $1.07 | $3.05 |
| Market cap | $20.61M | $17.59M |
| 1-day change | 0.00% | -2.09% |
| YTD return | +9.18% | +60.26% |
| 1-year return | -12.30% | -83.72% |
| 5-year return | -90.51% | -99.68% |
| P/E ratio (TTM) | — | 5.86 |
| EPS (TTM) | $-0.76 | $0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.03 | $18.52 |
| 52-week low | $0.76 | $1.83 |
| Distance from 52-week high | -47.29% | -83.56% |
| Analyst consensus | none | none |
| Avg. price target upside | +741.12% | +655.34% |
| Average volume | 55.91K | 9.63K |
| Shares outstanding | 19.26M | 5.78M |
| Employees | 10 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COCP has outperformed NCEL by 71.4 percentage points over the past year.
About Cocrystal Pharma
COCP stock →Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
COCP vs NCEL FAQ
Which is bigger, Cocrystal Pharma or NewcelX?
Cocrystal Pharma (COCP) is larger, with a market capitalization of $20.61M compared with $17.59M for NewcelX (NCEL).
Which stock has performed better over the past year, COCP or NCEL?
COCP returned -12.30% over the past 12 months, compared with -83.72% for NCEL (price return, excluding dividends). Past performance does not predict future results.
Are Cocrystal Pharma and NewcelX in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.